Alliance A021602: Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Everolimus (CABINET)

Objective

This randomized phase III trial studies cabozantinib S-malate to see how well it works compared with placebo in treating patients with neuroendocrine tumors previously treated with everolimus that have spread to nearby tissues or lymph nodes, have spread to other places in the body, or cannot be removed by surgery. Cabozantinib S-malate is a chemotherapy drug known as a tyrosine kinase inhibitor, and it targets specific tyrosine kinase receptors, that when blocked, may slow tumor growth.

https://clinicaltrials.gov/ct2/show/NCT03375320

Location: Essentia Health Cancer Centers

Research Study Categories

• Adult Studies

Specialty

• Gastrointestinal Cancer

Contact

Cancer Clinical Trials at 844-681-7944
or cancertrials@essentiahelath.org